05:42 AM EDT, 04/08/2024 (MT Newswires) -- Replimune Group ( REPL ) said Sunday that a phase 1/2 clinical trial of its RP1 monotherapy for skin cancer has initially showed an overall response rate of 34.8%.

The interim overall response rate comes from eight out of 23 evaluable patients, including five complete and three incomplete responses, the company said.

The trial evaluates the therapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, according to Replimune ( REPL ).

There was no evidence of transplant rejection during the trial, Replimune ( REPL ) said, adding that RP1 monotherapy was well tolerated.

Price: 7.35, Change: -0.01, Percent Change: -0.14